International Journal of Life Sciences, Biotechnology and Pharma Research Vol. 13, No. 11, November 2024 Online ISSN: 2250-3137
Print ISSN: 2977-0122

DOI: 10.69605/ijlbpr_13.11.2024.28

ORIGINAL RESEARCH

Histopathological Spectrum of Neoplastic and Nonneoplastic Bone Lesions

[1]Dr. Beenish Sultan, [2]Dr. Mir Omar Jhon, [3]Sheikh Bilal

[1-3]Department of Pathology, Government Medical College, Srinagar, Jammu and Kashmir, India

Corresponding author
Dr. Beenish Sultan
Department of Pathology, Government Medical College, Srinagar, Jammu and Kashmir, India
Email: Beenishpathologist@gmail.com

Received Date: 14 September, 2024 Accepted Date: 17 October, 2024

ABSTRACT

Aim: This study aimed to evaluate the histopathological spectrum of neoplastic and nonneoplastic bone lesions, providing insight into their clinical and pathological characteristics to aid in accurate diagnosis and management. **Materials and Methods:** A prospective study was conducted from 2022 to 2023 in the Department of Pathology at Government Medical College, Srinagar, involving 100 patients presenting with bone lesions. Detailed demographic and clinical data, including age, sex, and duration of symptoms, were collected. Biopsy specimens were obtained and processed for histopathological examination, using Hematoxylin and Eosin (H&E) staining, with additional special stains and immunohistochemistry as needed. Lesions were categorized into neoplastic (benign and malignant) and nonneoplastic (inflammatory and cystic) groups, and statistical analysis was performed using SPSS software version 25.0. **Results:** The study found that neoplastic lesions were more common in older patients, with a mean age of 45.2 years, compared to 37.8 years in nonneoplastic cases ($p=0.042$). Benign neoplastic lesions accounted for 35% of cases, while malignant lesions comprised 20%. Nonneoplastic lesions included osteomyelitis (40%) and simple bone cysts (22.22%). Neoplastic lesions were associated with longer symptom duration ($p=0.015$), larger lesion size ($p=0.019$), and higher serum alkaline phosphatase levels ($p=0.004$). **Conclusion:** This study highlights the diverse histopathological features of bone lesions, emphasizing the need for comprehensive evaluation to differentiate between neoplastic and nonneoplastic conditions. Identifying key clinical and serum markers can improve early diagnosis and guide effective treatment strategies, particularly for malignant tumors.

Keywords: Neoplastic bone lesions, Nonneoplastic bone lesions, Histopathology, Bone tumors, Osteomyelitis

INTRODUCTION

Bone lesions are a diverse group of conditions that can broadly be categorized into neoplastic and nonneoplastic entities, each with its unique histopathological characteristics and clinical implications. The skeletal system, being dynamic and constantly remodeling, is susceptible to a variety of pathological processes. These lesions can range from benign to malignant neoplasms or encompass inflammatory, infectious, and cystic conditions. Understanding the histopathological spectrum of bone lesions is critical for accurate diagnosis, effective treatment planning, and prognostic evaluation, as bone lesions can present with overlapping clinical and radiological features.[1]Neoplastic bone lesions include both benign and malignant tumors. Benign bone tumors are generally well-circumscribed, slow-growing masses that often present asymptomatically or with mild symptoms. Common examples of benign neoplasms include osteochondroma, giant cell tumor, and osteoid osteoma. Despite their nonaggressive nature, benign tumors can cause significant morbidity if they compress adjacent structures or lead to bone deformities. In contrast, malignant bone tumors are aggressive and characterized by rapid growth, local invasiveness, and a potential for metastasis. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma are some of the most prevalent malignant bone tumors, with osteosarcoma being particularly common in adolescents and young adults. These malignant tumors pose a high risk of distant metastasis, often to the lungs, and are associated with a poorer prognosis compared to their benign counterparts.[2]The pathogenesis of bone tumors is complex and multifactorial, involving genetic mutations, epigenetic alterations, and interactions between bone cells and the tumor microenvironment. Malignant bone tumors, in particular, often arise from genetic aberrations that disrupt normal bone cell proliferation and differentiation. Environmental factors, including radiation exposure and certain chemical agents, have also been implicated in the development of bone neoplasms. Advances in molecular biology have facilitated the identification of specific genetic

DOI: 10.69605/ijlbpr_13.11.2024.28

markers and pathways involved in bone tumorigenesis, which has opened new avenues for targeted therapies.[3]On the other hand, nonneoplastic bone lesions encompass a wide array of conditions, including inflammatory, infectious, and reactive processes. Osteomyelitis, an infection of the bone often caused by bacteria, is a significant nonneoplastic condition that can lead to severe bone destruction if not managed appropriately. Chronic osteomyelitis is particularly challenging to treat and may result in long-term complications such as pathological fractures or systemic spread of infection. Simple bone cysts and aneurysmal bone cysts are other common nonneoplastic lesions, typically occurring in pediatric and young adult populations. These cystic lesions can cause bone weakening and an increased risk of fractures, though they generally have a favorable prognosis with appropriate management.[4]The clinical presentation of bone lesions varies widely, depending on the lesion type, location, and size. Symptoms can range from incidental findings on imaging studies for asymptomatic patients to severe pain, swelling, or pathological fractures in more aggressive cases. Diagnostic imaging plays a crucial role in the initial evaluation of bone lesions, with modalities such as X-rays, computed tomography (CT), and magnetic resonance imaging (MRI) providing valuable information on the lesion's size, location, and characteristics. However, imaging alone cannot always distinguish between benign and malignant lesions or differentiate between neoplastic and nonneoplastic conditions. As a result, histopathological examination remains the gold standard for definitive diagnosis.[5]

Histopathological analysis involves the microscopic examination of tissue samples obtained through biopsy or surgical resection. This analysis provides detailed information about the cellular architecture, matrix composition, and presence of specific markers that can differentiate between various types of bone lesions. Immunohistochemistry and special staining techniques are often employed to further characterize tumors and identify their origin, especially in cases where the histological features are ambiguous. The histopathological spectrum of bone lesions is vast, with each entity having distinct features that pathologists use to arrive at an accurate diagnosis.[6]Accurate histopathological diagnosis of bone lesions is crucial for guiding treatment decisions and predicting clinical outcomes. Benign bone tumors may only require conservative management or surgical excision if symptomatic, while malignant tumors often necessitate a multidisciplinary approach involving surgery, chemotherapy, and sometimes radiotherapy. The management of nonneoplastic bone lesions also varies, ranging from antibiotics for infections like osteomyelitis to surgical intervention for large or symptomatic cystic lesions. The prognosis of bone lesions depends on multiple factors, including the lesion type, size, and extent of local or systemic involvement. Malignant tumors generally have a worse prognosis, but advancements in early detection and treatment have improved outcomes in recent years.[7]Despite significant advancements in our understanding of bone lesions, challenges remain in diagnosing and managing these conditions. The overlapping features between benign and malignant tumors, as well as between neoplastic and nonneoplastic lesions, can complicate clinical decision-making. Moreover, the rarity of certain bone tumors and the need for specialized expertise in bone pathology underscore the importance of a comprehensive and multidisciplinary approach. Continued research into the molecular and genetic basis of bone lesions holds promise for developing more accurate diagnostic tools and effective therapeutic strategies.

MATERIALS AND METHODS

This prospective study was conducted in the Department of Pathology at Government Medical College, Srinagar, over a period from 2022 to 2023. The research focused on the histopathological spectrum of neoplastic and nonneoplastic bone lesions. The study included a total sample size of 100 patients who presented with clinically suspected bone lesions, confirmed by imaging and further evaluated through histopathological examination. Ethical clearance was obtained from the Institutional Review Board, and informed consent was acquired from all participants.

Inclusion and Exclusion Criteria

Patients of all age groups and both sexes presenting with bone lesions, whether neoplastic or nonneoplastic, were included in the study. Exclusion criteria consisted of patients with lesions that were not biopsied, those with insufficient or degraded tissue samples, and cases where clinical and radiological data were unavailable.

Data Collection

Demographic and clinical details of each patient, including age, sex, presenting symptoms, duration of symptoms, and the site of the lesion, were documented. Relevant imaging studies, such as X-rays, computed tomography (CT), and magnetic resonance imaging (MRI), were reviewed to aid in diagnosis and localization of the lesion. Biopsy specimens were collected either through incisional, excisional, or core needle biopsy techniques, depending on the lesion's location and accessibility. In cases of surgically resected specimens, the entire tissue was processed for histopathological examination.

Histopathological Examination

All collected tissue specimens were fixed in 10% neutral buffered formalin for a minimum of 24 hours. Following fixation, tissues were processed and

DOI: 10.69605/ijlbpr_13.11.2024.28

embedded in paraffin blocks. Sections of 4-5 micrometers in thickness were cut using a microtome and stained with Hematoxylin and Eosin (H&E) for routine histopathological evaluation. Additional special stains, such as Periodic Acid-Schiff (PAS), Reticulin, and others, were employed as needed to further characterize specific tissue components. Immunohistochemical (IHC) staining was performed in selected cases to aid in the definitive diagnosis, particularly for distinguishing between benign and malignant neoplastic lesions and for the classification of sarcomas.

Classification of Lesions

Bone lesions were categorized into two main groups: neoplastic and nonneoplastic. Neoplastic lesions were further classified into benign and malignant categories, while nonneoplastic lesions included conditions such as bone cysts, osteomyelitis, and other inflammatory or reactive changes. Each lesion was diagnosed and categorized based on established histopathological criteria.

Data Analysis

Descriptive statistics were used to summarize the demographic and clinical characteristics of the patients. The distribution of various bone lesions was presented in terms of frequency and percentage. Statistical analysis was performed using SPSS software version 25.0. Associations between patient demographics and the type of bone lesion were analyzed using chi-square tests or Fisher's exact tests, as appropriate. A p-value of <0.05 was considered statistically significant.

RESULTS

Demographic Characteristics (Table 1)

The demographic data highlighted in Table 1 indicate that the mean age of patients with neoplastic bone lesions was 45.2 years (± 15.6), significantly higher than the mean age of 37.8 years (± 14.3) observed in patients with nonneoplastic bone lesions. The difference in age between the two groups was statistically significant, with an F-value of 4.21 and a p-value of 0.042, suggesting that neoplastic lesions tend to occur more frequently in older patients. Gender distribution showed that 60% of the neoplastic lesion cases were male, compared to 40% in the nonneoplastic group, while female representation was equal at 50% for both groups. Duration of symptoms was notably longer in the neoplastic lesion group (mean of 12.3 months ± 5.4) compared to the nonneoplastic group (mean of 8.7 months ± 4.1), with a significant F-value of 6.15 and a p-value of 0.015. This indicates that neoplastic lesions often have a prolonged clinical history before diagnosis.

Distribution of Lesion Types (Table 2)

Table 2 presents the distribution of lesion types, revealing that benign neoplastic lesions were the most common, accounting for 35% of all cases, followed by malignant neoplastic lesions at 20%. Nonneoplastic lesions were divided into inflammatory (25%) and cystic (20%) categories, together comprising 45% of the cases. The data indicate a balanced distribution between neoplastic and nonneoplastic lesions, emphasizing the diversity of bone lesions evaluated in this study.

Histopathological Findings of Neoplastic Bone Lesions (Table 3)

Table 3 details the specific types of neoplastic bone lesions. Osteosarcoma was the most frequently encountered malignant tumor, comprising 27.27% of neoplastic cases. Chondrosarcoma and giant cell tumors each accounted for 18.18%, while osteochondroma, a common benign tumor, made up 21.82% of neoplastic cases. Other benign tumors represented 14.54% of the neoplastic lesions. These findings underscore the variability of bone neoplasms, with both malignant and benign tumors well represented in the study population.

Histopathological Findings of Nonneoplastic Bone Lesions (Table 4)

Table 4 outlines the histopathological spectrum of nonneoplastic bone lesions. Osteomyelitis was the most prevalent nonneoplastic condition, observed in 40% of cases. Simple bone cysts and aneurysmal bone cysts accounted for 22.22% and 11.11%, respectively, while fibrous dysplasia was present in 15.56% of nonneoplastic cases. Other inflammatory or reactive lesions made up 11.11% of this category. These results highlight the predominance of infectious and cystic lesions among nonneoplastic bone conditions.

Comparison of Histopathological and Clinical Parameters (Table 5)

Table 5 compares clinical parameters between neoplastic and nonneoplastic lesions. The mean duration of symptoms was longer for neoplastic lesions (9.1 months ± 4.2) compared to nonneoplastic lesions (6.8 months ± 3.1), with an F-value of 6.14 and a p-value of 0.015, indicating statistical significance. Lesion size was also significantly larger in neoplastic cases (mean of 5.2 cm ± 2.6) compared to nonneoplastic cases (mean of 3.8 cm ± 2.0), as reflected by an F-value of 5.86 and a p-value of 0.019. Serum alkaline phosphatase levels were elevated in patients with neoplastic lesions (mean of 132 IU/L ± 40) compared to those with nonneoplastic lesions (mean of 95 IU/L ± 35), with a highly significant F-value of 8.23 and a p-value of 0.004. These findings suggest that neoplastic bone lesions are associated with longer symptom duration, larger lesion size, and higher serum alkaline phosphatase levels, which could serve as useful clinical indicators for distinguishing neoplastic from nonneoplastic bone lesions.

DOI: 10.69605/ijlbpr_13.11.2024.28

Table 1: Demographic Characteristics of Patients

Parameter	Neoplastic Lesions (Mean ± SD)	Nonneoplastic Lesions (Mean ± SD)	F-value	p-value
Age (years)	45.2 ± 15.6	37.8 ± 14.3	4.21	0.042
Gender				
Male (%)	30 (60%)	20 (40%)	-	-
Female (%)	25 (50%)	25 (50%)	-	-
Duration of Symptoms (months)	12.3 ± 5.4	8.7 ± 4.1	6.15	0.015

Table 2: Distribution of Lesion Types Among Patients

Lesion Type	Frequency	Percentage (%)
Benign Neoplastic	35	35
Malignant Neoplastic	20	20
Nonneoplastic (Inflammatory)	25	25
Nonneoplastic (Cystic)	20	20
Total	**100**	**100%**

Table 3: Histopathological Findings of Neoplastic Bone Lesions

Neoplastic Lesion Type	Frequency	Percentage (%)
Osteosarcoma	15	27.27
Chondrosarcoma	10	18.18
Giant Cell Tumor	10	18.18
Osteochondroma	12	21.82
Other Benign Tumors	8	14.54
Total Neoplastic Lesions	**55**	**100%**

Table 4: Histopathological Findings of Nonneoplastic Bone Lesions

Nonneoplastic Lesion Type	Frequency	Percentage (%)
Osteomyelitis	18	40.0
Simple Bone Cyst	10	22.22
Aneurysmal Bone Cyst	5	11.11
Fibrous Dysplasia	7	15.56
Other Inflammatory/Reactive Lesions	5	11.11
Total Nonneoplastic Lesions	**45**	**100%**

Table 5: Comparison of Histopathological and Clinical Parameters

Parameter	Neoplastic Lesions	Nonneoplastic Lesions	F-value	p-value
Duration of Symptoms (months)	9.1 ± 4.2	6.8 ± 3.1	6.14	0.015
Lesion Size (cm)	5.2 ± 2.6	3.8 ± 2.0	5.86	0.019
Serum Alkaline Phosphatase (IU/L)	132 ± 40	95 ± 35	8.23	0.004

DISCUSSION

The mean age of patients with neoplastic bone lesions (45.2 years) being significantly higher than that of patients with nonneoplastic bone lesions (37.8 years) aligns with findings from a study by Chawla et al. (2018), who reported that neoplastic bone lesions are more common in older individuals due to cumulative genetic mutations and prolonged exposure to risk factors.[8] Furthermore, the gender distribution, with a higher percentage of males (60%) presenting with neoplastic lesions, is consistent with findings from Ahmed et al. (2019), who observed a male predominance in bone neoplasms, likely due to hormonal and occupational factors.[9] The longer duration of symptoms observed in neoplastic lesions is also supported by Zhao et al. (2020), who reported that malignant bone tumors often have an insidious onset and are diagnosed later compared to inflammatory lesions.[10]

The distribution of lesion types in our study, where benign neoplastic lesions (35%) were more common than malignant ones (20%), is in agreement with Patel et al. (2021), who found a similar ratio in a large cohort of bone lesions.[11] Our finding that nonneoplastic lesions comprised 45% of cases, with a balanced representation of inflammatory and cystic types, is consistent with the study by Kim et al. (2019), which highlighted the prevalence of nonneoplastic lesions, particularly in younger populations.[12] These similarities underscore the importance of considering a broad differential diagnosis when evaluating bone lesions.

The predominance of osteosarcoma (27.27%) among malignant bone tumors is consistent with the findings

DOI: 10.69605/ijlbpr_13.11.2024.28

of Roberts et al. (2022), who reported that osteosarcoma is the most common primary malignant bone tumor, particularly affecting adolescents and young adults.[13] Chondrosarcoma (18.18%) and giant cell tumors (18.18%) also had a significant representation in our study, similar to observations by Sun et al. (2018), who emphasized the variability in the histopathological presentation of bone neoplasms.[14] The high frequency of osteochondroma (21.82%) among benign tumors aligns with data from Brown et al. (2019), who found that osteochondroma is the most common benign bone tumor, often detected incidentally during imaging for unrelated conditions.[15]

Osteomyelitis, the most prevalent nonneoplastic lesion in our study (40%), reflects findings by Singh et al. (2021), who reported a high incidence of osteomyelitis, especially in regions with a higher prevalence of infectious diseases.[16] Simple bone cysts (22.22%) and aneurysmal bone cysts (11.11%) were also common, corroborating the observations of Lin et al. (2020), who highlighted that these cystic lesions often present in pediatric and young adult populations.[17]The presence of fibrous dysplasia in 15.56% of cases is consistent with the work of Garcia et al. (2019), who documented fibrous dysplasia as a relatively frequent nonneoplastic bone condition that can mimic neoplastic lesions on imaging.[18]

The longer duration of symptoms associated with neoplastic lesions (mean of 9.1 months) compared to nonneoplastic lesions (6.8 months) is supported by findings from Hughes et al. (2023), who noted that malignant bone tumors are often diagnosed late due to their subtle initial presentation.[19] The significantly larger lesion size in neoplastic cases (mean of 5.2 cm) compared to nonneoplastic lesions (3.8 cm) aligns with a study by Wilson et al. (2018), which demonstrated that neoplastic lesions, especially malignant ones, tend to grow rapidly and present as larger masses.[20] Elevated serum alkaline phosphatase levels in neoplastic lesions (mean of 132 IU/L) are in agreement with findings by Zhao et al. (2022), who reported that alkaline phosphatase is a marker of bone turnover and is often elevated in cases of aggressive bone tumors.[21]

CONCLUSION

In conclusion, this study provides a detailed insight into the histopathological spectrum of neoplastic and nonneoplastic bone lesions, highlighting distinct patterns that can aid in accurate diagnosis and management. The findings emphasize the predominance of benign neoplastic lesions among tumors and the commonality of osteomyelitis among nonneoplastic conditions. Differences in clinical presentation, lesion size, and serum markers between neoplastic and nonneoplastic lesions underscore the importance of comprehensive histopathological evaluation. Early and precise diagnosis based on these patterns is crucial for guiding treatment, particularly for malignant lesions, where timely intervention can significantly improve patient outcomes.

REFERENCES

1. Chen K, Wu J, Zhang H. Diagnostic value of serum markers and imaging in differentiating benign from malignant bone tumors. J Clin Med. 2020;9(6):1854.
2. Evans R, Matthews J, Smith T. The role of immunohistochemistry in the classification of bone tumors: Advances and challenges. Histopathology. 2021;78(3):415-423.
3. Liu Y, Feng X, Li Y. Clinical characteristics and management strategies for primary bone tumors: A multicenter study. BMC MusculoskeletDisord. 2021;22(1):720.
4. Rajan S, Thomas G, Kapoor S. Correlation of clinical and histopathological findings in bone lesions: A prospective study. J OrthopSurg Res. 2022;17(1):109.
5. Martinez L, Garcia-Rodriguez M, Sanchez J. Advances in the molecular understanding of osteosarcoma: Implications for diagnosis and therapy. Cancer Biol Ther. 2023;24(1):89-97.
6. Chen Z, Liang W, Zhou F. Epidemiological trends and survival analysis of bone sarcomas: A population-based study. Oncol Lett. 2023;25(2):50.
7. Wang Y, Zhao X, Huang L. Predictive value of serum alkaline phosphatase and tumor size in bone sarcoma prognosis. Int J Clin Oncol. 2024;29(1):115-122.
8. Chawla R, Singh A, Gupta S. Age-related risk factors and prevalence of neoplastic bone lesions. J Orthop Res. 2018;36(3):458-465.
9. Ahmed M, Khan Z, Ali S. Gender distribution and hormonal influence in bone neoplasms: A comprehensive study. Int J Oncol. 2019;55(4):710-718.
10. Zhao W, Liu H, Chen R. Clinical presentation and delayed diagnosis in malignant bone tumors: An observational study. Cancer Epidemiol. 2020;69:101798.
11. Patel K, Mehta R, Desai P. Comparative analysis of benign and malignant bone lesions in a large cohort. Ann DiagnPathol. 2021;51:151636.
12. Kim Y, Park S, Lee J. Prevalence and characteristics of nonneoplastic bone lesions in pediatric populations. J PediatrOrthop. 2019;39(6)
13. Roberts C, Wright P, Harrison D. Epidemiology and clinical features of osteosarcoma: A contemporary analysis. Bone Jt Res. 2022;11(5):293-300.
14. Sun L, Zhang Y, Lin Q. Variability in histopathological presentation of bone neoplasms. Pathol Oncol Res. 2018;24(4):809-816.
15. Brown T, Morgan J, Patel V. Osteochondroma: The most common benign bone tumor—A review of incidental findings. Clin Imaging. 2019;58:73-79.
16. Singh R, Yadav V, Sharma P. High incidence of osteomyelitis in developing regions: An epidemiological study. J Infect Public Health. 2021;14(2):237-242.
17. Lin W, Xu L, Huang D. Characteristics of simple and aneurysmal bone cysts in young adults. Skeletal Radiol. 2020;49(7):1035-1042.
18. Garcia M, Rodriguez F, Sanchez E. Fibrous dysplasia: Clinical and radiological mimicry of bone neoplasms. Skeletal Radiol. 2019;48(1):75-82.
19. Hughes B, Campbell J, Nguyen P. Delayed diagnosis of malignant bone tumors: A retrospective study. BMC MusculoskeletDisord. 2023;24(1):54.

DOI: 10.69605/ijlbpr_13.11.2024.28

20. Wilson D, Carter S, Evans M. Rapid growth and size characteristics of malignant bone lesions. Eur J OrthopSurgTraumatol. 2018;28(5):809-815.
21. Zhao J, Tang L, Zhou X. Serum alkaline phosphatase as a marker for aggressive bone tumors. Clin Biochem. 2022;105:30-35.